Full-Time
Commercial services for pharmaceutical lifecycle management
No salary listed
Madrid, Spain
Remote
| , |
EVERSANA provides integrated commercial services to pharmaceutical and biotech companies across the product lifecycle. It helps with drug pricing, market access, reimbursement, patient adherence, and product delivery through a service-based model. Its solutions are delivered via a global network of 30+ locations, including consulting, market access strategies, patient services, and field deployment. The goal is to help clients bring products to market, optimize pricing and access, improve adherence, and ensure efficient delivery to improve patient outcomes and commercial performance.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Milwaukee, Wisconsin
Founded
2018
Help us improve and share your feedback! Did you find this helpful?
People at EVERSANA who can refer or advise you
Health Insurance
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Mental Health Support
Conference Attendance Budget
EVERSANA names new chief legal officer. EVERSANA has named Monica Avram as Executive Vice President and Chief Legal Officer, a strategic addition as the company scales operations and reinvents commercialization services. As Chief Legal Officer and a member of the Executive Leadership Team, Monica leads the company's global Legal and Compliance function. Her strategic leadership integrates governance, risk, and operational execution to enable innovation, strengthen enterprise performance, and drive long-term value. With more than two decades of experience at top law firms and across global Fortune 100 companies - including UnitedHealth Group and Sanofi - Avram brings deep expertise at the intersection of healthcare, law, and emerging technologies. She has built high-performing, financially disciplined legal teams, advised executive leadership and boards on enterprise strategy, and guided organizations through complex regulatory and operational environments. "As we continue to scale, it's paramount that we have top talent who can understand the complexity of our industry and bring proven track records of success," said Mark Thierer, CEO, EVERSANA. "Throughout her career, Monica has demonstrated exceptional leadership in building best-in-class legal organizations, and we're thrilled to welcome her to EVERSANA." She brings seasoned board and advisory experience across public companies and nonprofit organizations, with deep expertise in governance, oversight, and strategic leadership. Avram holds a BA in Biology from the University of Missouri - Kansas City and a Juris Doctor from Suffolk University Law School.
Trinity has announced the acquisition of EVERSANA's advisory services operation in the Asia-Pacific and Middle East (APACME) regions. This strategic move will transition EVERSANA's APACME advisory services to Trinity, enhancing its global presence in life sciences commercialization solutions.
OWP Pharmaceuticals selects EVERSANA to support U.S. Launch of SUBVENITE(R)(lamotrigine) Oral Suspension. News provided by. CHICAGO, Oct. 23, 2025 /PRNewswire/ - OWP Pharmaceuticals, a privately held, commercial-stage neuroscience specialty pharmaceutical company, today announced that EVERSANA(R), a leading provider of commercialization services to the global life sciences industry, will provide U.S. commercialization services for the launch of SUBVENITE(R)(lamotrigine) oral suspension, the company's novel treatment for epilepsy and bipolar disorders. SUBVENITE(R), approved by the U.S. Food and Drug Administration on September 16, 2025, is the first and only FDA-approved lamotrigine oral suspension in the U.S. It is designed to help improve access to epilepsy treatments as a flexible, patient-friendly alternative to tablets. Lamotrigine is widely prescribed, but is now available in a ready-to-use liquid version. SUBVENITE(R) Oral Suspension is ideal for patients who have difficulty swallowing tablets, those who require individualized dosing, or prefer liquid medication formulations. To support a successful product launch, EVERSANA is currently activating an array of services, including field deployment, data & analytics, and co-pay services. The SUBVENITE(R) launch support is part of EVERSANA and OWP's broader commercialization partnership announced in January 2022. "Market access challenges continue to be the major hurdle for patients looking for new treatment options," said Gregory Skalicky, President, EVERSANA. "Together with OWP Pharmaceuticals, we're removing barriers and helping patients find new hope." OWP Pharmaceutical's commitment to innovation for patients expands beyond the United States. Since its founding in 2014, the company has developed a unique partnership with the ROW Foundation to support humanitarian efforts for people worldwide with epilepsy. As innovative new solutions like SUBVENITE become available, OWP is committed to ensuring it reaches patients in need, as nearly 80% of people with epilepsy live in underdeveloped countries, and about 75% of them do not have access to a treatment option. "Working with EVERSANA to support commercialization efforts in the U.S. is an important milestone for patients," said Scott Boyer, Founder and President, OWP Pharmaceuticals. "But our vision continues to be much larger, that every epilepsy patient globally one day might have access through OWP Pharma and ROW Foundation, the Pharmaceutical Social Enterprise(R). To learn more about OWP Pharmaceuticals, visit www.owppharma.com. About EVERSANA EVERSANA(R) is a leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and X. About OWP Pharmaceuticals OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations. Based in Lisle, IL, OWP is committed to advancing therapies in neurology and psychiatry, with a mission to bring meaningful innovations to patients. Through its partnership with the ROW Foundation, OWP also supports global initiatives to improve epilepsy care and education in underserved communities worldwide. For EVERSANA Matt Braun Vice President, Corporate Communications [email protected] SOURCE EVERSANA; OWP Pharmaceuticals
Eversana, a company that helps drugmakers sell their medicines, has acquired a smaller firm called Waltz Health that helps employers and health insurance companies purchase cheaper drugs, in a bid to build an alternative to traditional pharmacy benefits middlemen in the U.S.